The objective of this study is to use immunohistochemistry to determine whether myofibroblastic proliferations (MFPs) are a distinct entity or a variation of other fibroblastic entities. Staining patterns of vimentin, SMA and CD34 are evaluated in irritation fibromas, ulcerated fibromas, giant cell fibromas, inflammatory fibrous hyperplasias, focal keratosis and chronic mucositis, used in this study as a control group, and MFPs. This study assesses whether MFPs demonstrate similar staining patterns of vimentin, SMA and CD34 to the aforementioned lesions and if these stains are adequate in differentiating the entities. Upon IRB approval, 46 cases of irritation fibroma, 45 cases of ulcerated irritation fibroma, 44 cases of giant cell fibroma, 47 cases of focal keratosis and chronic mucositis, and 23 cases of MFPs were collected. Hematoxylin and eosin-stained slides were reviewed and immunohistochemistry of vimentin, SMA and CD34 was performed. Staining patterns were graded as 0, 1 and 2 (≤25%; ≤25-50%; and ≥50% respectively). Differences were analyzed by the Kruskal-Wallis exact test and Dunn's test for pairwise comparisons. Vimentin demonstrated grade 2 positivity in all groups with 6.5% and 4.4% of irritation fibromas and MFPs demonstrating grade 1 positivity, respectively. Smooth muscle actin was strongly positive in MFPs (78.3%, grade 2, p < 0.05) but also demonstrated positivity in focal keratosis and chronic mucositis (2.1% grade 1), giant cell fibromas (4.6% grade 1, 4.6% grade 2), inflammatory fibrous hyperplasias (13.6% grade 1, 13.6% grade 2) and ulcerated irritation fibromas (6.7% grade 2, 8.9% grade 1) though this was not statistically significant. CD34 demonstrated statistically significant positivity in irritation fibromas (87% grade 2, 2.2% grade 1), ulcerated irritation fibromas (73.3%